Generative AI advancements on the verge of gulping down Human-Jobs

China has emerged as the global leader in industrial robot installation, with over 50% of the world’s total, particularly in the electronics, automotive, and metal sectors. However, despite advancements in AI, robots still face mechanical limitations in entirely replacing human workers. Investors like Future Capital and Lenovo Capital are backing companies like LimX and Pan Motor, focusing on humanoid robots and motors. Generative AI aids in advanced task planning for humanoid robots while reducing costs in pharmaceutical research by minimizing failed experiments. 

Founders Space, working with Chinese startup Fastra, anticipates mass robot production within a year, aiming to lower costs to $50,000 to $100,000 per robot. With robots capable of working continuously and charging as they work, the return on investment could be achieved within a year. Insilico Medicine, leveraging AI, claims to have reduced the cost of pharmaceutical research by synthesizing fewer molecules for testing and completing phase 2 clinical trials for an AI-generated drug, as published in Nature in March.

[Image Source: Forbes]